addendum_to_2023_affordability_review_summary_repo.pdf
Enbrel Supply and Program Information from Amgen Reviewed
Trusted by teams at
Description
The Prescription Drug Affordability Board reviewed Enbrel, manufactured and supplied by Amgen Inc., as part of its 2023 drug affordability assessment. Voluntarily submitted documentation and assistance program information from Amgen were considered in the report.
Contract Details
Vendor
AMGEN INC
Agency
Colorado Division of Insurance, CO
Contract Type
SUPPLIES
Document Date
May 23, 2025
Renewal Info
Enbrel remains under contract for supply through pharmacies and healthcare providers for approved indications. No biosimilar entry anticipated before 2029 due to patent protections. Annual review may occur.
More from AMGEN INC
Related Contracts
wake_county_board_of_commissioners_meeting_agenda.pdf
PENDINGwake-county-meeting-agenda-2025-01-06_d5e.pdf
PENDINGHolly Springs Town Council Agenda December 2024
APPROVEDcentral-michigan-university-meeting-minutes-2023-06-29_959.pdf
More from Colorado Division of Insurance
addendum_to_2023_affordability_review_summary_repo.pdf
addendum_to_2023_affordability_review_summary_repo.pdf
addendum_to_2023_affordability_review_summary_repo.pdf
Colorado Prescription Drug Affordability Board Meeting October 2024
Colorado Prescription Drug Affordability Board Meeting October 2024
Want to learn more?
Get alerts on contract renewals, new awards, and vendor activity.
Bring us your territory.
We'll show you what is forming.
See live SLED buying signals, source docs, decision-makers, contract context, and the next step into your CRM or pipeline.